Literature DB >> 28410853

Use of organism identification by 16S ribosomal RNA polymerase chain reaction to shorten antimicrobial length of therapy.

Elise M Gilbert1, Filiz Yucebay2, Mike Malczynski3, Danielle Smith4, John S Esterly1, Chao Qi5, Michael Postelnick6, Milena M McLaughlin7.   

Abstract

BACKGROUND: Organism detection by 16S ribosomal RNA (rRNA) PCR followed by amplicon sequencing identification may help guide antimicrobial treatment in culture-negative patients. The objectives of this study were to assess the effect of a positive versus negative 16S rRNA PCR on antibiotic length of therapy (LOT) and rate of antibiotic discontinuation.
METHODS: Patients with a sterile site, direct-specimen 16S rRNA PCR negative, and suspected active infection were matched 1:1 with 16S rRNA PCR positive patients based on specimen site and retrospectively evaluated.
RESULTS: Ninety patients were included (n=45 positive and negative). 16S rRNA PCR negative patients had shorter median LOT (33days [IQR 8-46] versus 43days [IQR 29-51], P=0.02). Antibiotics were discontinued more frequently in 16S rRNA PCR negative patients (38% versus 4%, P<0.01).
CONCLUSIONS: For culture-negative patients with suspected sterile site infection, a negative, direct-specimen 16S rRNA PCR may help discontinue antibiotics and decrease LOT.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibiotic use; Polymerase chain reaction

Mesh:

Substances:

Year:  2017        PMID: 28410853     DOI: 10.1016/j.diagmicrobio.2017.03.013

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  1 in total

Review 1.  Microbial Identification Using DNA Target Amplification and Sequencing: Clinical Utility and Impact on Patient Management.

Authors:  Tinzar Basein; Bradley J Gardiner; Gabriela M Andujar Vazquez; Andrew S Joel Chandranesan; Arthur R Rabson; Shira Doron; David R Snydman
Journal:  Open Forum Infect Dis       Date:  2018-10-10       Impact factor: 3.835

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.